Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Acumen Pharmaceuticals, Inc.

NASDAQ: ABOS · Life Sciences · 5 alerts · CIK 1576885

Share price
$0.2160Close, Nov 16
Market cap
$15.6M
Shares outstanding
72.33MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Acumen Pharmaceuticals, Inc. filings on SEC EDGAR ↗

7:06 AM ET 8-K
Clinical Trial Data

Acumen Pharmaceuticals Clinical Trial Data

Acumen Pharmaceuticals announced that its Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer’s disease failed to meet its primary endpoint of cognitive and functional decline improvement. The trial also failed key secondary endpoints, leading the company to cease development of sabirnetug and implement cash conservation measures while exploring strategic options.

Term
18 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.